Stock Events

Stock Events

Renalytix 

$0.02
0
+$0+0% Friday 17:38

Statistics

Day High
0.04
Day Low
0.04
52W High
0.18
52W Low
0.04
Volume
10,000
Avg. Volume
81
Mkt Cap
7.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q4 0
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q4 2025
-0.04
-0.03
-0.02
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,986.46%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
4.58MRevenue
-90.94MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RENXF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bio-Rad Laboratories
BIO
Mkt Cap6.81B
Bio-Rad Laboratories offers a range of products for the clinical diagnostics market, competing in the same space as Renalytix's kidney diagnostic solutions.
Quest Diagnostics
DGX
Mkt Cap20.74B
Quest Diagnostics provides diagnostic testing, information, and services, including for kidney function, directly competing with Renalytix's offerings.
Labcorp
LH
Mkt Cap20.84B
Laboratory Corporation of America Holdings operates in the same clinical laboratory services sector, offering tests that overlap with Renalytix's kidney health diagnostics.
Guardant Health
GH
Mkt Cap12.69B
Guardant Health operates in the precision oncology field but competes with Renalytix through its development of diagnostics that could overlap with kidney disease detection.
Fulgent Genetics
FLGT
Mkt Cap453.27M
Fulgent Genetics provides comprehensive genetic testing, directly competing in the genetic markers space for diseases, including those related to the kidney.
QuidelOrtho
QDEL
Mkt Cap737.83M
QuidelOrtho Corporation is a provider of diagnostic testing solutions that compete with Renalytix by offering tests that can be used in diagnosing kidney conditions.
Neogenomics
NEO
Mkt Cap1.17B
NeoGenomics specializes in cancer diagnostics and testing services but competes with Renalytix by offering tests that could be relevant for kidney disease patients.
Thermo Fisher Scientific
TMO
Mkt Cap172.8B
Thermo Fisher Scientific offers a wide range of healthcare solutions, including diagnostics that compete with Renalytix's kidney disease diagnostic products.

About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Show more...
CEO
Mr. James R. McCullough M.B.A.
Country
United States
ISIN
GB00BYWL4Y04

Listings

OTC Link
US
RENXF
MU
DE
2O9.MU
MU
DE
2O90.MU
STU
DE
2O90.STU

0 Comments

Share your thoughts

FAQ

What is Renalytix stock price today?▼
The current price of RENXF is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Renalytix stock price performance more closely on the chart.
What is Renalytix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Renalytix stocks are traded under the ticker RENXF.
What is Renalytix market cap?▼
Today Renalytix has the market capitalization of 7.65M
When is the next Renalytix earnings date?▼
Renalytix is going to release the next earnings report on November 03, 2026.
What is Renalytix revenue for the last year?▼
Renalytix revenue for the last year amounts to 4.58M USD.
What is Renalytix net income for the last year?▼
RENXF net income for the last year is -90.94M USD.
In which sector is Renalytix located?▼
Renalytix operates in the Other sector.
When did Renalytix complete a stock split?▼
Renalytix has not had any recent stock splits.
Where is Renalytix headquartered?▼
Renalytix is headquartered in London, United States.